Pharmacovigilance

Contacts

Pharmacovigilance

Phi implemented more than a decade ago a medical department that ensures safety use and medical information of our medicines.

We created a pharmacovigilance unit in accordance with good practices that collects and monitors adverse events reported by health professionals related to our medicines. One of our mission is to contribute to the collection of information reported from healthcare professionals and transmit them to the national center of pharmacovigilance with whom we are in close collaboration. Also, our medical representatives are trained on PHI pharmacovigilance procedures and are aware of the importance of these reports for the safety of our medicines.

Besides that, the medical department ensures relevance and reliability of the information provided by our representatives on our drugs. Regular and updated medical trainings allow them to be commited to medical ethics.

We invite healthcare professionals and patients to inform us about any suspected adverse event related to our medicines.

PHI Pharmacovigilance Contact

Email : pharmacovigilance@phi.ma

Phone : 05.37.74.82.84 / 85 /86

Fax : 05.37.74.86.39

National Center of Pharmacovigilance Contact

Website : www.capm.ma

Phone : 05.37.68.64.64

N° Eco : 0801.000.180

Pharmacovigilance : Adverse event report form

REPORTER OR INITIALS

Name :

Occupation :

Address :

E-mail :

Phone :

Date :

PATIENT

Gender :
WomanMan

Initials :

Age or date of birth :

MEDICAL HISTORY :

SUSPECT DRUG

Drug name :

Batch number :

Route :

Dosing :

Start date :

Stop date :

Indication :

Causality (according to reporter) :

CONCOMITANT MEDICATION(S)

Taken at time of event (do not write down medications prescribed for adverse event treatment) :

ADVERSE EVENT(S)

Onset date :

Resolution date :

Thank you to complete your contact details so we can reach out to you.

Seriousness criteria :
DeathDisabilityHospitalization or prolonged hospitalizationMedically significant according to reporterLife threateningCongenital anomaly / Birth defect

We want to take this opportunity to thank you for your inquiry. Please note that any personal data provided by you will be treated by PHI with full respect of your privacy and you have the right to access your personal data. Any information you provide, including an adverse event or product quality complaint, may be shared with regulatory agencies, our company subsidiaries, and business partners with whom we have contractual agreements. These individuals may be located in a country other than yours.

In case you wish to access, amend or correct your personal health information, please contact us at (+212 537 64 83 64) or at (pharmacovigilance@phi.ma).